OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use
Open Access
- 13 October 2022
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 16, 3405-3413
Abstract
Purpose: To evaluate OC-01 [varenicline solution nasal spray (VNS)] tear production and symptom outcomes in patients with dry eye disease by age, gender, race, ethnicity, and artificial tear use status. Patients and Methods: Adults ≥ 22 years of age diagnosed with dry eye disease, with Ocular Surface Disease Index score ≥ 23, corneal fluorescein staining score ≥ 2 in ≥ 1 region or ≥ 4 for all regions, and baseline Schirmer Test Score (STS) ≤ 10 mm, with no restrictions on eye dryness score (EDS). Efficacy was assessed using integrated data from ONSET-1 and ONSET-2 [vehicle control (VC), n=294; OC-01 VNS 0.03 mg, n=308]. Subgroups included age (≤ 55, 56− 65, > 65 years), gender (male, female), race (White, Black or African American), ethnicity (Hispanic or Latino, Not Hispanic or Latino), and artificial tear use (yes, no). Analysis of covariance models, with the covariates treatment, study site, and baseline severity measures, were used to calculate treatment−VC differences. Consistency of effect among subgroups was evaluated by conducting interaction tests. Results: Consistency of treatment effect across subgroups was observed for all endpoints, with P value for all treatment−subgroup interaction terms > 0.05. For % of patients with ≥ 10mm improvement in STS and least squares (LS) mean change from baseline in STS and EDS, there was improvement in tear production across demographic group categories. Artificial tear use did not change STS or EDS outcomes with OC-01 VNS. Conclusion: OC-01 VNS improved tear production and patient-reported symptom outcomes across a broad range of patients by age, gender, race, and ethnicity, and regardless of artificial tear use status at baseline. OC-01 VNS demonstrated a consistent benefit across an extensive range of patients with dry eye disease.Keywords
This publication has 23 references indexed in Scilit:
- Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye DiseaseOphthalmology, 2022
- Biological functions of tear filmExperimental Eye Research, 2020
- Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and OlderAmerican Journal of Ophthalmology, 2017
- TFOS DEWS II Epidemiology ReportThe Ocular Surface, 2017
- TFOS DEWS II Definition and Classification ReportThe Ocular Surface, 2017
- TFOS DEWS II Tear Film ReportThe Ocular Surface, 2017
- Randomized Controlled Crossover Trial Comparing the Impact of Sham or Intranasal Tear Neurostimulation on Conjunctival Goblet Cell DegranulationAmerican Journal of Ophthalmology, 2017
- Over the counter (OTC) artificial tear drops for dry eye syndromeCochrane Database of Systematic Reviews, 2016
- Complexity of the tear film: Importance in homeostasis and dysfunction during diseaseExperimental Eye Research, 2013
- Neural regulation of lacrimal gland secretory processes: Relevance in dry eye diseasesProgress in Retinal and Eye Research, 2009